ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,918.25
0.00%
US Tech 100
20,610.80
0.00%
다우존스 지수
42,635.20
0.00%
Bitcoin
92,715.31
-2.46%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Recursion Pharmaceuticals Inc (RXRX)

  7. Recursion Pharmaceuticals Inc (RXRX) 뉴스

RXRX

Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:RXRX
일자시간출처헤드라인심볼기업
2025/01/0900:30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2025/01/0723:15GlobeNewswire Inc.Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & MoreNASDAQ:RXRXRecursion Pharmaceuticals Inc
2025/01/0708:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2025/01/0708:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2025/01/0708:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2025/01/0622:30GlobeNewswire Inc.Recursion to Present at 43rd Annual JP Morgan Healthcare ConferenceNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/2706:24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/2106:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/2106:05GlobeNewswire Inc.Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/1908:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/1807:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/1807:05Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/1206:48Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/1106:56Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/1008:00GlobeNewswire Inc.Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable TolerabilityNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/0707:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/0600:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/0500:32Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/0406:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/0322:30GlobeNewswire Inc.Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and LymphomaNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/12/0309:02Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/11/2806:09Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/11/2706:48Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/11/2308:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/11/2308:25Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/11/2206:24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/11/2021:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/11/2021:11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/11/2021:00GlobeNewswire Inc.Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discoveryNASDAQ:RXRXRecursion Pharmaceuticals Inc
2024/11/2008:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
 검색 관련기사 보기:NASDAQ:RXRX

최근 히스토리

NASDAQ
AMZN
Amazon.com
COIN
DOGEUSD
Dogecoin
NYSE
KO
Coca Cola
NASDAQ
GOOGL
Alphabet
COIN
AVAXUSD
Avalanche
CCOM
SILVER
SILVER
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
DIS
Walt Disney
NASDAQ
NVDA
NVIDIA
CCOM
US100
US Tech 100
COIN
ETHUSD
Ethereum
NYSE
XOM
Exxon Mobil
NASDAQ
AAPL
Apple
COIN
ADAUSD
Cardano
NYSE
CVX
Chevron
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유